Related Experiment Videos
[Estrogen receptor and selective estrogen receptor modulators (SERMs)].
1Second Department of Internal Medicine, Osaka City University Medical School.
Nihon Rinsho. Japanese Journal of Clinical Medicine
|June 11, 1999
Summary
Selective estrogen receptor modulators (SERMs) offer a promising alternative to estrogen therapy for postmenopausal women, preventing bone loss and improving cholesterol without increasing cancer risk. These compounds target estrogen receptors (ERs) to provide tissue-specific effects.
Area of Science:
- Endocrinology
- Pharmacology
- Molecular Biology
Context:
- Postmenopausal women face increased risks of osteoporosis and cardiovascular disease.
- Estrogen replacement therapy (ERT) prevents these conditions but carries risks of endometrial and breast cancer.
- A therapy is needed to protect bone and cardiovascular health without stimulating reproductive tissues.
Purpose:
- To review the role of selective estrogen receptor modulators (SERMs) in postmenopausal health.
- To discuss the mechanisms of SERMs, focusing on their interaction with estrogen receptors (ERs).
- To explore the involvement of ER alpha and ER beta in SERM-mediated tissue-selective pharmacology.
Summary:
- SERMs, like raloxifene and tamoxifen, mimic estrogen's beneficial effects on bone and lipids while blocking estrogen's action in reproductive tissues.
- SERMs achieve tissue selectivity through high-affinity binding to estrogen receptors (ERs).
- Both ER alpha and ER beta are implicated in the complex signaling pathways underlying SERM activity.
Impact:
- SERMs represent a potential therapeutic strategy for managing postmenopausal health concerns.
- Understanding ER alpha and ER beta roles can lead to the development of more targeted and effective treatments.
- This review highlights novel signal transduction pathways relevant to SERM action.